A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma ; volume:9 ; number:1 ; day:27 ; month:7 ; year:2018 ; pages:1-14 ; date:12.2018
Nature Communications ; 9, Heft 1 (27.7.2018), 1-14, 12.2018
- Creator
-
Chen, Xiaoyue
- Contributor
-
Zhang, Minjie
Gan, Haiyun
Wang, Heping
Lee, Jeong-Heon
Fang, Dong
Kitange, Gaspar J.
He, Lihong
Hu, Zeng
Parney, Ian F.
Meyer, Fredric B.
Giannini, Caterina
Sarkaria, Jann N.
Zhang, Zhiguo
SpringerLink (Online service)
- DOI
-
10.1038/s41467-018-05373-4
- URN
-
urn:nbn:de:101:1-2018092522170989288778
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chen, Xiaoyue
- Zhang, Minjie
- Gan, Haiyun
- Wang, Heping
- Lee, Jeong-Heon
- Fang, Dong
- Kitange, Gaspar J.
- He, Lihong
- Hu, Zeng
- Parney, Ian F.
- Meyer, Fredric B.
- Giannini, Caterina
- Sarkaria, Jann N.
- Zhang, Zhiguo
- SpringerLink (Online service)
Other Objects (12)
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT
PLEKHG5 regulates autophagy, survival and MGMT expression in U251-MG glioblastoma cells
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Accelerated hyperfractionation plus temozolomide in glioblastoma
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT
PLEKHG5 regulates autophagy, survival and MGMT expression in U251-MG glioblastoma cells
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Accelerated hyperfractionation plus temozolomide in glioblastoma
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT
PLEKHG5 regulates autophagy, survival and MGMT expression in U251-MG glioblastoma cells
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter